Zacks Research Analysts Raise Earnings Estimates for BHC

Bausch Health Cos Inc. (NYSE:BHC – Free Report) – Equities researchers at Zacks Research increased their Q4 2026 earnings per share estimates for Bausch Health Cos in a research report issued on Wednesday, November 18th. Zacks Research analyst Team now anticipates that the company will post earnings of $1.17 per share for the quarter, up from their prior estimate of $1.16. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.78 per share. Zacks Research also issued estimates for Bausch Health Cos’ Q1 2027 earnings at $0.85 EPS, Q2 2027 earnings at $0.95 EPS, Q3 2027 earnings at $1.05 EPS, Q4 2027 earnings at $1.05 EPS, FY2027 earnings at $3.89 EPS, Q1 2028 earnings at $0.68 EPS and Q2 2028 earnings at $0.89 EPS.

BHC has been the subject of several other reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Bausch Health Cos in a research note on Thursday, October 29th. Jefferies Financial Group increased their price objective on shares of Bausch Health Cos from $6.50 to $8.00 and gave the stock a “hold” rating in a research report on Thursday, October 29th. Royal Bank Of Canada raised their target price on Bausch Health Cos from $9.00 to $10.00 and gave the company a “sector perform” rating in a research note on Thursday, October 29th. Barclays raised their target price on Bausch Health Cos from $7.00 to $9.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 11th. Finally, Wall Street Zen raised Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Six investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bausch Health Cos has a consensus rating of “Reduce” and a consensus price target of $8.75.

Check Out Our Latest Analysis on BHC

Bausch Health Cos Trading Down 4.0%

NYSE:BHC opened at $8.22 on Thursday. The stock has a market capitalization of $3.08 billion, a price-to-earnings ratio of -3.59 and a beta of 0.30. The firm has a fifty day simple moving average of $6.80 and a two-hundred day simple moving average of $5.87. Bausch Health Cos has a 12 month low of $4.33 and a 12 month high of $9.04.

Bausch Health Cos (NYSE:BHC – Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The company reported $1.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.52. The firm had revenue of $2.90 billion for the quarter, compared to analyst estimates of $2.72 billion. Bausch Health Cos had a negative return on equity of 401.73% and a negative net margin of 7.57%.

Institutional Trading of Bausch Health Cos

Several hedge funds have recently bought and sold shares of the business. Paulson & CO. Inc. bought a new stake in Bausch Health Cos during the second quarter worth $361,151,000. The Manufacturers Life Insurance Company purchased a new stake in Bausch Health Cos in the 2nd quarter valued at $1,167,000. Dimensional Fund Advisors LP lifted its stake in Bausch Health Cos by 10.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 3,604,818 shares of the company’s stock valued at $19,456,000 after acquiring an additional 350,823 shares in the last quarter. MFN Partners Management LP bought a new position in Bausch Health Cos during the 2nd quarter valued at $29,580,000. Finally, Bank of America Corp DE bought a new position in Bausch Health Cos during the 2nd quarter valued at $2,816,000. Institutional investors and hedge funds own 78.65% of the company’s stock.

Trending Headlines about Bausch Health Cos

Here are a few of the latest headlines about BHC:

  • Positive Sentiment: Solta Medical, Bausch Health’s aesthetics business, said its portfolio has surpassed 10 million treatments worldwide—an adoption milestone for products including Thermage and Fraxel. Solta Medical surpasses 10 million treatments worldwide
  • Neutral Sentiment: Zacks Research’s estimate changes were mixed overall: it also trimmed FY2028 EPS to $3.03 from $3.05 and Q3 2027 EPS to $1.05 from $1.07, while keeping its “Hold” rating.
  • Negative Sentiment: The clearest downgrade was to Q3 2028 EPS, cut to $0.72 from $0.82, indicating a weaker outlook for that quarter.

Bausch Health Cos Company Profile

(Get Free Report)

Bausch Health Companies Inc. is a global specialty pharmaceutical and medical products company headquartered in Laval, Quebec. It develops, manufactures and markets prescription medicines, over-the-counter products and medical devices, with businesses spanning eye health, gastroenterology, dermatology, neurology and aesthetics. Its portfolio includes Salix products for gastrointestinal conditions, Ortho Dermatologics treatments for skin conditions and Solta Medical aesthetic devices. Bausch Health also retains a controlling ownership interest in Bausch + Lomb, a publicly traded eye-health company whose products include contact lenses, lens care products, pharmaceuticals and surgical devices.

Recommended Stories

Earnings History and Estimates for Bausch Health Cos (NYSE:BHC)

Receive News & Ratings for Bausch Health Cos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Cos and related companies with MarketBeat.com's FREE daily email newsletter.